Analytical Data
-
Gene name
CEACAM3
- Application
-
Alternative Names
CD66d; CEA; CD66-D; CGM1; W264; W282; Carcinoembryonic antigen CGM1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 97% as determined by reducing SDS-PAGE.
-
Uniprot
P40198
-
Expression Region
Lys35~Glu190
-
Molecular Weight
18kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CEACAM3, or Carcinoembryonic Antigen-related Cell Adhesion Molecule 3, is a member of the CEACAM family of proteins, which are primarily involved in immune responses and cell adhesion processes. Research on CEACAM3 has gained traction due to its role as a receptor for certain pathogens, including Neisseria gonorrhoeae, and its implications in inflammatory responses and cancer biology. It is predominantly expressed on the surface of neutrophils, where it participates in the modulation of immune signaling pathways. The study of recombinant CEACAM3 proteins has provided valuable insights into its structural and functional characteristics, facilitating the understanding of its interactions with ligands and its role in host-pathogen interactions. Additionally, recombinant CEACAM3 is being explored for its potential applications in therapeutic interventions, including the development of vaccines and immune modulators. The ability to produce CEACAM3 in recombinant form allows for advanced studies, including crystallography and biochemical assays, which can elucidate its mechanism of action and pave the way for targeted therapies in infectious diseases and cancer. Overall, the ongoing research into CEACAM3 and its recombinant forms underscores its significance in immunology and pathology, offering promising avenues for novel therapeutic strategies.
